Alcon has terminated its definitive merger agreement with STAAR Surgical Company, originally announced on August 5, 2025. According to Alcon CEO David J. Endicott, the company remained disciplined regarding price and risk throughout the process. Alcon’s refractive strategy remains unchanged, with continued focus on its new wavelight® plus offering for LASIK and ongoing global launches of more than 10 major products in its surgical and vision care franchises.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106685027) on January 07, 2026, and is solely responsible for the information contained therein.
Comments